Potential Efficacy of Anti-PD-1 or PD-L1 Antibody Treatments for Gynecologic Cancers

Journal Title: Women's Health – Open Journal - Year 2017, Vol 3, Issue 3

Abstract

Programmed cell death-1 (PD-1; CD279) is an immunosuppressive co-inhibitory molecule that belongs to the CD28 family of receptors on T-cells. It was discovered by Ishida et al in 1992.1 The most important peripheral regulatory pathway is the interaction between the PD-1 receptor, expressed on T-cells, and programmed cell death ligands-1 and 2 (PD-L1 and PD-L2) on the cancer cell surface.2 This immune checkpoint exists in a normal physiological state to protect against autoimmunity and inflammation. In a neoplastic state, dysfunction of these immune checkpoint proteins can lead to tumor tolerance and eventually allow tumors to ‘escape’ from the immune system. PD-1 blockage enhances the proliferation of transferred T-cells at the tumor site. In addition, the combination of adoptive T-cell transfer and anti-PD-1 antibody results in significant inhibition of tumor progression.3 These therapeutic effects of PD-1 blockage require the INF-γ signal. Targeting the molecules that regulate the immune response using the new drug nivolumab, an anti-PD-1 antibody has been the subject of much research and has yielded some promising and exciting results.

Authors and Affiliations

Masafumi Koshiyama

Keywords

Related Articles

Hormone Replacement Therapy and its Risks and Benefits for Women

There is no doubt that as both women and men age, the decline in the hormones which in their earlier years kept them vigorous and youthful has impacted dramatically on their health. Hormonal balance plays an integral rol...

Chronic Diseases during Pregnancy and Birth Outcome: A Study Based on Tertiary Hospital of Mumbai

Background/Objective: Chronic disease has emerged as one of the most serious public health problems while disease prevalence during pregnancy had a greater risk of premature death and long-term illness. However, it is an...

Perception of Fatigue in Female Nurses Employed in Hospitals

Background: Fatigue is the inability to maintain the required stamina in work capacity with consequences affecting occupational performance, health, and safety. Women are often more exposed to the risk of fatigue because...

Iron Deficiency in Women

It is a well known fact that anaemia can give rise to a range of problems for people who suffer from it.1 In what follows, I will be concentrating on elaborating some of the subtle health issues surrounding anaemia. Anae...

Violence Against Women: A Global Perspective

Violence against women is rampant in all corners of the world and devastates the lives of millions of women. It is rooted in a global culture of discrimination which denies women equal rights with men, legitimizing the a...

Download PDF file
  • EP ID EP554947
  • DOI 10.17140/WHOJ-3-e013
  • Views 138
  • Downloads 0

How To Cite

Masafumi Koshiyama (2017). Potential Efficacy of Anti-PD-1 or PD-L1 Antibody Treatments for Gynecologic Cancers. Women's Health – Open Journal, 3(3), 21-23. https://europub.co.uk/articles/-A-554947